咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >The Research Progress of Bioin... 收藏
The Research Progress of Bioinformatics-Led Design of Single...

The Research Progress of Bioinformatics-Led Design of Single-Chain Antibody Molecules

作     者:Guo-Yong Shan Jian-Hua Zhang 

作者单位:Department of Radiation Oncology Zhengzhou People's Hospital The Faculty of Biomedical Engineering Zhengzhou University 

会议名称:《The 2011 International Conference on Information Technology and Agricultural Engineering(ICITAE 2011)》

会议日期:2011年

学科分类:1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学] 

基  金:partially supported by the science and technology plan projects of development and support of Zhengzhou city(No.0910SGYS33377-1) the natural sciences plan projects of education department of Henan province(No.2010A310018) 

关 键 词:Single-chain antibody Fusion genes Bioinformatics Structure– activity relationship 

摘      要:The development of single-chain antibody(scF v) by recombinant gene expression is an important milestone for cancer gene therapy. Single-chain antibodies are reconstructed for cancer-targeted therapy to provide good penetration into tumor tissue and to improve their pharmacokinetics in vivo, offering a clinically valuable application. However, there may be some variation between the structure and function of the fusion proteins. Analyzing the interaction region between the antibody and the antigen, and the binding sites for molecular conformation, it is clear that the existing antibodies need to be modified, enhancing the biological activity of the antibodies. Based on the view that bio-molecular computer models are closely integrated with biological experiments, a bio-molecular structure–activity relationship model can be established in terms of molecular conformation, physical and chemical properties and the biological activity of single-chain antibodies. On the one hand, the structure–activity relationship is clear for new immune molecules at the gene expression level. On the other hand, a single-chain antibody molecule can be designed and optimized for the cancer-oriented treatment. In this review, we provide the theoretical and experimental basis for the development of singlechain antibodies appropriate for cancer therapy.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分